32A9, a novel human antibody for designing an immunotoxin and CAR-T cells against glypican-3 in hepatocellular carcinoma

32A9, a novel human antibody for designing an immunotoxin and CAR-T cells against glypican-3 in hepatocellular carcinoma

Abstract Background Treatment of hepatocellular carcinoma (HCC) using antibody-based targeted therapies, such as antibody conjugates and chimeric antigen receptor T (CAR-T) cell therapy, shows potent antitumor efficacy. Glypican-3 (GPC3) is an emerging HCC therapeutic target; therefore, antibodies a...

Full description

Bibliographic Details
Main Authors: Xiaoyu Liu, Fang Gao, Longwei Jiang, Meng Jia, Lei Ao, Ming Lu, Liming Gou, Mitchell Ho, Shaochang Jia, Fei Chen, Wei Gao
Format: Article
Language:English
Published: BMC 2020-08-01
Series:Journal of Translational Medicine
Subjects:
Liver cancer
Glypican-3
Antibody
Immunotoxin
Chimeric antigen receptor
Online Access:http://link.springer.com/article/10.1186/s12967-020-02462-1

Internet

http://link.springer.com/article/10.1186/s12967-020-02462-1

Similar Items